Zealthy Review
Best for: not currently recommended — listed for transparency and reader awareness only
Zealthy (legal entity FitRX, LLC, recently renamed to Gronk Inc.) offers compounded semaglutide and tirzepatide via an asynchronous telehealth model. Listed here for completeness with full disclosure of two FDA warning letters and active federal litigation — see warnings and cons sections before considering.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Zealthy is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Starting | compounded | $286 |
| Starting | compounded | $351 |
✓ Pros
- •34 states served — meaningful nationwide footprint
- •Asynchronous model removes friction for patients comfortable without a synchronous video visit
- •Independent licensed prescribers retain full clinical authority
✗ Cons
- •TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
- •Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
- •Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
- •Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
- •Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
- •Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
- •Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
- •Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
Ready to start with Zealthy?
Starting at $286/month. See current pricing and start your free consultation.
Sources & methodology
Our Zealthy review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Zealthy
Alan Meds
Best for: budget-conscious shoppers
Editorial score · methodology
Amazon Pharmacy
Best for: fastest brand-name Foundayo delivery with the cheapest insured price
Editorial score · methodology
AmberHealth
Best for: budget-conscious shoppers
Editorial score · methodology
Frequently Asked Questions
Ready to start with Zealthy?
Starting at $286/month. See current pricing and start your free consultation.